HC Wainwright Estimates Lifeward’s Q1 Earnings (NASDAQ:LFWD)

Lifeward Ltd. (NASDAQ:LFWD) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for Lifeward in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Lifeward’s current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Lifeward’s Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.54) EPS and FY2030 earnings at $3.20 EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Lifeward currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Lifeward Price Performance

Shares of LFWD opened at $7.68 on Wednesday. The company has a market cap of $21.58 million, a price-to-earnings ratio of -0.39 and a beta of 0.36. Lifeward has a 1-year low of $4.14 and a 1-year high of $15.18. The company’s fifty day simple moving average is $6.87 and its 200 day simple moving average is $7.06. The company has a current ratio of 2.40, a quick ratio of 1.82 and a debt-to-equity ratio of 1.16.

Lifeward (NASDAQ:LFWD) last issued its earnings results on Friday, May 15th. The company reported ($6.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52). The firm had revenue of $3.92 million for the quarter, compared to analyst estimates of $5.78 million. Lifeward had a negative return on equity of 243.14% and a negative net margin of 123.66%.

Hedge Funds Weigh In On Lifeward

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LP boosted its position in Lifeward by 149.7% during the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after purchasing an additional 29,423 shares during the period. Virtu Financial LLC boosted its position in Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares during the period. Jane Street Group LLC boosted its position in shares of Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock valued at $40,000 after acquiring an additional 29,927 shares during the period. Finally, Citadel Advisors LLC boosted its position in shares of Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after acquiring an additional 198,406 shares during the period. 26.76% of the stock is owned by institutional investors.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.